†These authors contributed equally.
Academic Editors: Brian Tomlinson, Takatoshi Kasai and Marco Zimarino
Background: Obstructive sleep apnea (OSA) is a common disorder
worldwide. It is associated with myocardial remodeling and arteriosclerosis in
patients with hypertension. Our study investigated the relationship between OSA
severity and arteriosclerosis and blood pressure in an Asian population.
Methods: We enrolled 365 subjects from July 2018 to December 2020 at
Ruijin Hospital. We recorded data from the medical history and collected blood
samples from all participants. We performed 24-hour ambulatory Blood Pressure
(BP) monitoring and Carotid-femoral pulse wave velocity (cf-PWV) measurements.
Overnight polysomnography (PSG) was performed using Respironics Alice
PDxSleepware. Results: PSG was performed in a total of 365 subjects;
mean age of 49.1
Obstructive sleep apnea (OSA) is a condition characterized by intermittent hypoxia, awakening, excessive respiratory effort, and excessive negative intrathoracic pressure fluctuations, resulting in increased sympathetic activity, oxidative stress, inflammation, endothelial dysfunction, vascular stiffness and insulin resistance [1, 2, 3]. Although apnea occurs only during sleep, the pathophysiological consequences of recurrent apnea do not subside upon awakening [4]. Each episode of apnea usually lasts a minute or less, but when repeated night after night, and for years or decades, the resulting hemodynamic and inflammatory disturbances can have long-term consequences for OSA patients. More evidence suggests that OSA is associated with increased cardiovascular events, such as myocardial infarction [5] and stroke [6]. We have also gradually recognized the relationship between OSA and cardiovascular disease, and tried to carry out early intervention (such as non-invasive positive airway pressure ventilation) to reduce the risk of subsequent cardiovascular disease. The current problem is how to early detect the cardiovascular risk of OSA patients and give early intervention according to possible targets. One study has shown that OSA is associated with myocardial remodeling and arteriosclerosis in patients with hypertension [7]. There are few studies on the relationship between OSA severity and arteriosclerosis and blood pressure in the Asian population. Whether this is an early assessment and intervention target is unknown. Carotid-femoral pulse wave velocity (cf-PWV) is a noninvasive and well-validated technique to assess arterial stiffness, which is a major factor determining arteriosclerosis due to degenerative medical changes in the arterial wall. OSA is a common disorder worldwide and is associated with myocardial remodeling and arteriosclerosis in patients with hypertension. Our study investigated the relationship between OSA severity and arteriosclerosis (measured by cf-PWV) and blood pressure in an Asian population. We hope to explore the early assessment and intervention targets of cardiovascular disease risk in patients with OSA.
The study was a cross-sectional analysis of 365 subjects from July 2018 to
December 2020 at Ruijin Hospital. We collected data from the
medical history (including past medical history, a smoking and alcohol intake
history) and anthropometric measurements, including hip circumference, waist
circumference, and body mass index (BMI). Blood samples were obtained in all
participants. Inclusion criteria: (1) Age
Carotid-femoral pulse wave velocity (cf-PWV) was measured by means of arterial pulse detection with applanation tonometry with a Millar transducer and SphygmoCor software (AtCor Medical, Sydney, Australia). cf-PWV measurement was doneby sequential registration of the femoral and carotid artery pulse and measuring the pulse transit time in relation to the R wave ofr the ECG signal. Pulse travel distance was measured from the suprasternal notch to the femoral and carotid artery sites and the subtraction distance method was used to determine cf-PWV from the foot-to-foot pulse transit time between the carotid and femoral pulses.
We performed 24-hour ambulatory Blood Pressure (BP) monitoring (Mobil-O-Graph PWA, IEM, Stolberg, Germany). BP was measured every 20 minutes during the day and every 30
minutes during the night with an appropriate cuff placed on the dominant arm.
Daytime values of systolic and diastolic BPs
Overnight polysomnography (PSG) (n = 365 subjects) was performed using
Respironics Alice PDxSleepware (Respironics, Inc., Murraysville, PA, USA,
CN1043844) digital equipment. Obstructive apnea was defined as a flat or nearly
flat amplitude of the nasal pressure signal (from peak to trough) for
Hypertension was defined as in the absence of antihypertensive drugs, blood
pressure
Continuous variables are presented as mean
PSG was performed in a total of 365 subjects. The clinical characteristics of
the study subjects are shown in (Table 1). A total of 365 subjects were studied
with a mean age of 49.1
Parameter | Mean |
Age (years) | 49.1 |
BMI (kg/m |
28.1 |
WHR | 1.0 |
Sex | |
Male (%) | 326 (89.3%) |
Female (%) | 39 (10.7%) |
HR (bpm) | 78 |
IMT (mm) | 0.7 |
LDL-c (mmol/L) | 3.3 |
FPG (mmol/L) | 5.9 |
HbA1C (%) | 6.1 |
eGFR (mL/min/1.73 m |
93.1 |
LVMI (g/m |
124.1 |
cf-PWV (m/s) | 9.5 |
Smoking (%) | 122 (33.4%) |
Drink (%) | 94 (25.8%) |
Diabetes | 75 (20.5%) |
Hypertension | 291 (79.7%) |
BMI, Body Mass Index; WHR, Waist-Hip ratio; HR, Heart Rate; IMT, intima-media thickness; eGFR, estimated Glomerular Filtration Rate; LVMI, PWV, pulse wave velocity; Left Ventricular Mass index; FPG, fasting plasma glucose; LDL-c, low-density lipoprotein cholesterol. |
The subjects were divided into two groups base on AHI severity. The office
systolic BP was significantly higher in the group with moderate to severe than
mild OSA subjects (148
Parameter | AHI |
AHI |
p value |
Age (year) | 44.6 |
50.9 |
|
BMI (kg/m |
27.5 |
28.3 |
|
HR (beat per minuite) | 82 |
77 |
|
WHR | 0.99 |
0.98 |
0.312 |
cf-PWV (m/s) | 7.62 |
10.03 |
|
AHI | 7.3 |
38.7 |
|
SpO |
84 |
76 |
|
LDL-c (mmol/L) | 3.10 |
3.33 |
0.32 |
FPG (mmol/L) | 5.43 |
0.69 |
|
HbA1C | 5.80 |
6.16 |
|
IMT (mm) | 0.72 |
0.72 |
0.949 |
LVMI (g/m |
122.86 |
124.54 |
0.644 |
eGFR (mL/min/1.73 m |
95.9 |
91.8 |
|
UA (umol/L) | 423.3 |
411.0 |
0.39 |
Diabetes (n) | 10 | 65 | |
Hypertension (n) | 75 | 216 | |
Smoking (n) | 28 | 94 | |
Drink (n) | 26 | 68 | 0.716 |
office-SBP (mmHg) | 139 |
148 |
|
office-DBP (mmHg) | 89 |
92 |
0.81 |
24 h SBP (mmHg) | 132 |
132 |
0.996 |
24 h DBP (mmHg) | 88 |
86 |
0.071 |
Day SBP (mmHg) | 135 |
134 |
0.788 |
Day DBP (mmHg) | 91 |
87 |
|
Night SBP (mmHg) | 127 |
126 |
0.932 |
Night DBP (mmHg) | 83 |
81 |
0.226 |
BMI, Body Mass Index; WHR, Waist-Hip ratio; HR, Heart Rate; IMT, intima-media thickness; eGFR, estimated Glomerular Filtration Rate; LVMI, Left Ventricular Mass index; PWV, pulse wave velocity; UA, uric acid; LDL-c, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; AHI, Apnea Hyponea Index. |
The subjects with moderate to severe OSA had significantly higher cf-PWV values
than the mild group (10.03
The comparison of PWV grouped by AHI. The subjects with AHI
The subjects with
moderate to severe OSA presented higher c-fPWV values than those in the mild
group (10.03
Age | BMI | PWV | AHI | N-SBP | N-DBP | HbA1c | eGFR | LDL-c | |
Age | |||||||||
BMI | –0.213** | ||||||||
PWV | 0.606** | –0.117 | |||||||
AHI | 0.148** | 0.228** | 0.217** | ||||||
Night SBP | –0.034 | 0.325** | 0.199** | 0.116 | |||||
Night DBP | –0.312** | 0.206** | –0.164* | 0.07 | 0.659** | ||||
HbA1c | 0.238** | 0.12 | 0.384** | 0.172** | 0.13 | –0.061 | |||
eGFR | –0.590** | 0.07 | –0.368** | –0.095 | 0.013 | 0.180** | –0.133 | ||
LDL-c | –0.125* | 0.057 | –0.111 | 0.045 | –0.08 | –0.046 | 0.181** | 0.018 | |
*p |
After adjusting for age, BMI, LDL-c, FGB, AHI, eGFR, Night BP, office diastolic BP and Day BP in Logistic regression model, AHI (OR = 1.03, 95% CI: 1.01–1.05) and office diastolic pressure (OR = 1.04, 95% CI: 1.00–1.08) and age (OR = 1.12, 95% CI: 1.06–1.19) were independent risk factors for arteriosclerosis (Table 4).
B | S.E | Wald | df | Sig | Exp (B) | 95% CI for EXP (B) | ||
lower | Upper | |||||||
Constant | –9.408 | 4.478 | 4.414 | 1 | 0.036 | 0.000 | ||
age | 0.115 | 0.028 | 16.771 | 1 | 0.000 | 1.122 | 1.062 | 1.186 |
BMI | –0.082 | 0.067 | 1.520 | 1 | 0.218 | 0.921 | 0.808 | 1.050 |
LDL-c | –0.233 | 0.198 | 1.380 | 1 | 0.240 | 0.792 | 0.537 | 1.168 |
FPG | 0.219 | 0.173 | 1.607 | 1 | 0.205 | 1.244 | 0.887 | 1.745 |
AHI | 0.030 | 0.011 | 7.920 | 1 | 0.005 | 1.031 | 1.009 | 1.052 |
eGFR | 0.001 | 0.017 | 0.005 | 1 | 0.942 | 1.001 | 0.969 | 1.034 |
Night-DBP | 0.005 | 0.031 | 0.024 | 1 | 0.877 | 1.005 | 0.945 | 1.069 |
o-DBP | 0.039 | 0.019 | 4.362 | 1 | 0.037 | 1.040 | 1.002 | 1.079 |
Day-DBP | –0.010 | 0.037 | 0.070 | 1 | 0.791 | 0.990 | 0.921 | 1.065 |
OSA is a common disorder worldwide. It is associated with increased cardiovascular morbidity and mortality. cf-PWV is a potent cardio-vascular risk marker for arterial stiffness. Higher cf-PWV has been shown to be associated with worse clinical outcomes [12]. This cross-sectional study analyzed the relationship between OSA and arterial stiffness in a Chinese population. Our study shows that cf-PWV was significantly higher in moderate to severe compared to mild OSA patients. AHI was significantly and positively correlated with cf-PWV, and was an independent risk factor for arteriosclerosis.
Our study found that cf-PWV was significantly higher in moderate to severe compared to mild OSA patients. Many studies have confirmed that OSA is related to impaired vascular function. For example, a recent meta-analysis showed that cf-PWV or AIx of OSA patients was significantly higher than that of healthy people [13]. Compared with a control group, patients with OSA without known cardiovascular disease have increased PWV [14]. Compared to a control group, OSA patients also have higher intima-media thickness and carotid diameter, similar to those in patients with hypertension [15]. Intermittent hypoxemia and oxidative stress may be the cause of impaired vascular function caused by OSA [16]. Intermittent hypoxia can lead to increase of inflammatory markers such as endothelin-1 (ET-1), interleukin-6 (IL-6), C-reactive protein (CRP) and nitric oxide (NO). These factors associated with inflammation can affect vascular endothelial function as well as promoting arteriosclerosis and inflammatory vascular remodelingarteriosclerosis [17].
In addition, the impact of day and night differences in certain influencing factors on PWV needs to be considered. For example, intermittent hypoxemia at night may lead to activation of inflammatory pathways, increased sympathetic tone and impaired endothelium-dependent vasodilation [18]. Patients who suffer from sleepiness during the day have more severe OSA and greater improvement in arterial stiffness after treatment with continuous positive airway pressure (CPAP). This may be because daytime sleepiness is related to the severity of inflammation associated with sleep disruption (wakefulness and sleep fragmentation) and decreased saturation at night [19]. Short-term (8 weeks) CPAP treatment has been shown to significantly improve central systolic blood pressure, aortic pulse wave velocity, aortic augmentation index in patients with moderate–severe OSA and in patients with metabolic syndrome (MS) [20] only in patients who used the device for a minimum of 4 h/night. The concentrated redistribution of body fluids during sleep is related to the high prevalence of drug-resistant hypertension and OSA, both of which show clinical features that indicate extracellular fluid volume overload [21]. Future research will study the correlation between OSA and PWV.
CPAP seems to be an effective method to improve arterial stiffness in OSA patients, but this has been contradicted by a study [22] that showed that CPAP treatment for 6 months was not associated with reduced aortic stiffness as measured by cf-PWV, in patients with resistant hypertension and moderate to severe OSA. However, in contrast to no-CPAP therapy, treatment may prevent its progression. The timing of initiating CPAP therapy and the duration of CPAP therapy may have a higher effect on the efficacy, which requires further research.
It is theorized that the severity of OSA has no independent effect on PWV [23]. However, our study suggests that the cf-PWV value of subjects with moderate to severe OSA was significantly higher than in those with mild OSA. Both OSA and high blood pressure can cause arterial stiffness and abnormality of heart structures. When these two conditions coexist, there will likely be a cumulative effect. The ventricular afterload increases and the heart remodels [7]. We therefore believe that the severity of OSA also affects arterial stiffness.
The results of this study suggest that the office systolic blood pressure in patients with moderate to severe OSA group was significantly higher than in those with mild OSA, but there was no difference between the office diastolic blood pressure, 24 h systolic blood pressure, 24 h diastolic blood pressure, and day and night BP between the two groups. AHI, office diastolic blood pressure and age are independent risk factors for arteriosclerosis.
Increasing age, increasing body size, hypertension and insulin resistance may all lead to increased OSA and arterial stiffness [23]. OSA can lead to marked nocturnal blood pressure fluctuations (NBPFs) and can be associated with increased arterial stiffness and nocturnal hypertension [24]. Of course, both pharmacological and nonpharmacological treatments, including antihypertensive therapy, will affect the association between OSA and blood pressure. CPAP therapy reduces NBPFs, arterial stiffness and nocturnal BP in patients with OSA and coexisting cardiovascular diseases [24]. Therefore, the correlation between blood pressure and OSA in this study may be interfered by the above confounding factors. In addition, the increased blood pressure in the office and the influence of occult hypertension cannot be ignored. For example, studies have suggested that compared with matched control groups, OSA patients have a higher incidence of unadjusted occult hypertension [25]. When OSA and hypertension coexist, there is an additive effect of subclinical arteriosclerosis markers. OSA may lead to poor blood pressure control, and its mechanisms include increased sympathetic nerve activity, decreased baroreflex sensitivity, disturbance of sodium metabolism and extracellular water distribution, impaired endothelial function, hypoxia and circulatory reoxygenation [16]. Therefore, we also need to emphasize the role of blood pressure control in OSA patients.
Our research also shows the correlation between HbA1c, BMI and AHI. There have been many studies on the correlation between obesity and OSA. The relationship between blood glucose, vessel function and OSA is complicated. A previous cross-sectional analysis showed that a decrease in heart rate variability (HRV) in young patients with type 1 diabetes was associated with an increase in arterial stiffness [26]. An association between HbA1c (hemoglobin A1c) and the severity of OSA and has been reported in both nondiabetic and diabetic cohorts [27, 28]. OSA is also a risk factor for lower extremity arterial disease (LEAD) in patients with type 2 diabetes [17]. The accumulation of advanced glycation end products (AGEs), insulin resistance, and excess reactive oxygen species (ROS) accumulation caused by hypoxia may be the pathophysiological mechanisms related to the three conditions [17].
This study has some limitations. First, the sample size was small, and the influence of lipid-regulating drugs and antiplatelet drugs was not excluded. Second, most subjects were male and we did not adjust for sex.
The severity of OSA was positively correlated with pulse wave velocity. AHI, office blood pressure and age were independent risk factors for arteriosclerosis. Further studies will enhance the sample size to investigate underlying relationships and potential mechanisms of arterial stiffness in patients with obstructive sleep apnea/hypopnea.
BMI, Body Mass Index; WHR, Waist-Hip ratio; HR, Heart Rate; IMT, intima-media thickness; LDL-c, low density lipoprotein cholesterin; FPG, fasting plasma glucose; eGFR, estimated Glomerular Filtration Rate; LVMI, Left Ventricular Mass index; cf-PWV, Carotid-femoral pulse wave velocity; PWV, pulse wave velocity; AHI, apnea-hypopnea index; OSA, Obstructive sleep apnea; UA, uric acid; BP, Blood Pressure; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; PSG, Overnight polysomnography.
BWT and JLZ designed the research study. YYB performed the research. HY and AA provided help and advice on BWT analyzed the data. BWT, JHZ and JLZ wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
All studies were in compliance with the Declaration of Helsinki, the Good Clinical Practice guidelines, and applicable regulatory requirements. All participants provided written informed consent to participate for the respective study, which was approved by the Human Research Ethics Committee at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (2017(1)-1).
We gratefully acknowledge the invaluable assistance of the physicians of the Department of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; the study would not have been possible without their support.
This research was funded by the National Natural Science Foundation of China (Grant No. 81500190), and Clinical Science and Shanghai Municipal Hospital New Frontier Technology Joint Project (SHDC12019X20), Shanghai Municipal Commission of Health and Family Planning (Grant No.2020YJZX0124).
The authors declare no conflict of interest.